Newly IPO’d Medpace sees Q3 revenue jump

Medpace ($MEDP) saw net service revenue hit $94.8 million for Q3, a jump of 16.1% compared to last year, as it enjoys life after its $160 million summer IPO.

The Cincinnati, OH-based CRO’s backlog at the end of September grew 14% to $480.4 million, while net new business awards were $109.1 million, representing a net book-to-bill ratio of 1.15x, for the third quarter.

Looking at the last nine months, net new business awards were $327.2 million, representing a book-to-bill ratio of 1.19x.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

These past three quarters were up on last year’s given its growth in oncology, CV and antiviral anti-infective therapeutic areas, the company said.

During Q3, Medpace also used the net proceeds from its IPO, as well as its available cash, to repay $210 million worth of loans, lowering its debt to $165 million.

The CRO’s cash and cash equivalents were $14.6 million at Sept. 30, 2016, while it made $42.2 million in cash flow from operating activities during Q3.

Medpace, which has a market cap of $1.29 billion, was up 2.4% on Monday, with its shares worth $31.72. It sold 8 million of its shares in its IPO back in mid-August for $23 apiece.  


Suggested Articles

Algernon has chosen contract research organization Novotech to help run its phase 2 idiopathic pulmonary fibrosis and chronic cough drug test.

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.